Estimating the fitness cost and benefit of antimicrobial resistance from pathogen genomic data https://www.biorxiv.org/content/10.1101/2022.12.02.518824v1?med=mas
CleverLibre Social is an inclusive social instance for open discussion, learning, and community. All cultures welcome. Hate speech and harassment strictly forbidden.